title: Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
abstract: OBJECTIVE
  To identify the 140-kd autoantigen recognized by anti-155/140 autoantibodies that are associated with adult cancer-associated dermatomyositis (DM) and juvenile DM and to determine the clinical relevance of anti-155/140 antibodies in a large cohort.
  
  
  METHODS
  Sera from 456 DM patients were assessed for the presence of anti-155/140 antibodies by immunoprecipitation using K562 cell extracts as substrate. Using immunoprecipitation and Western blotting, we then examined whether anti-155/140-positive sera recognized transcription intermediary factor 1α (TIF-1α), TIF-1β, and TIF-1γ. The clinical associations of antigen reactivity were also evaluated.
  
  
  RESULTS
  Anti-155/140-positive sera reacted with 140-kd TIF-1α in addition to 155-kd TIF-1γ. Among sera from 456 DM patients, 52 were reactive with both TIF-1α and TIF-1γ, while another 25 were reactive with TIF-1γ alone. Additionally, 7 were reactive with TIF-1β. Malignancy was more frequently found in adult patients with both anti-TIF-1α and anti-TIF-1γ antibodies than in those with anti-TIF-1γ antibodies alone (73% versus 50%; P < 0.05). In addition to juvenile DM patients and middle-aged and older DM patients with high percentages of malignancy, 8 "young adult" DM patients without malignancy had these autoantibodies.
  
  
  CONCLUSIONS
  Anti-155/140 antibodies target TIF-1 family proteins, TIF-1α and TIF-1β, in addition to TIF-1γ. Since TIF-1 proteins have significant roles in oncogenesis, these antibodies may be produced during misdirected antitumor immunity.
authors: Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan. fujimoto-m@umin.ac.jp
authors: Manabu
authors: M
authors: Fujimoto
authors: Yasuhito
authors: Y
authors: Hamaguchi
authors: Kenzo
authors: K
authors: Kaji
authors: Takashi
authors: T
authors: Matsushita
authors: Yuki
authors: Y
authors: Ichimura
authors: Masanari
authors: M
authors: Kodera
authors: Naoko
authors: N
authors: Ishiguro
authors: Ikuko
authors: I
authors: Ueda-Hayakawa
authors: Yoshihide
authors: Y
authors: Asano
authors: Fumihide
authors: F
authors: Ogawa
authors: Keita
authors: K
authors: Fujikawa
authors: Takuya
authors: T
authors: Miyagi
authors: Eriko
authors: E
authors: Mabuchi
authors: Kenji
authors: K
authors: Hirose
authors: Narihiro
authors: N
authors: Akimoto
authors: Naohito
authors: N
authors: Hatta
authors: Kiyohiro
authors: K
authors: Tsutsui
authors: Akira
authors: A
authors: Higashi
authors: Atsuyuki
authors: A
authors: Igarashi
authors: Mariko
authors: M
authors: Seishima
authors: Minoru
authors: M
authors: Hasegawa
authors: Kazuhiko
authors: K
authors: Takehara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology*; D003882:Dermatomyositis / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology*; D014157:Transcription Factors / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D009687:Nuclear Proteins; D014157:Transcription Factors; C093517:transcriptional intermediary factor 1